Seattle Clinical Research Center is pleased to announce that the FDA has approved a new treatment for axillary hyperhidrosis, also known as excessive underarm sweating. This is a chronic skin condition that affects approximately 10 million people in the United States and causes people to sweat more than what is necessary for normal thermal regulation.
The approved treatment, Qbrexza cloth, is an anticholinergic that is used as a topical treatment. Qbrexza is applied directly to the underarm skin and is designed to block sweat production by inhibiting sweat gland activation. The wipes are approved to treat adults and children over the age of 9 and are expected to be available in October 2018.
Dr. Robin Kroll, director of Seattle Clinical Research Center comments, “Data shows that excessive underarm sweating has a negative impact on an individual’s well-being and can cause emotional, social, physiological and even occupational impairment. Not only is it embarrassing, but it can complicate business and social interactions. I am hopeful that Qbrexza will be a new treatment option that will reduce the impact this condition has on their life.”